Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160218393> ?p ?o ?g. }
- W3160218393 endingPage "1332" @default.
- W3160218393 startingPage "1317" @default.
- W3160218393 abstract "Introduction Different single-tablet regimens (STRs), containing one or two nucleoside reverse transcriptase inhibitors (NRTIs) plus an anchor drug, are available for the use in naïve, HIV-infected patients. Despite some restrictions in the use of particular regimens in certain situations (e.g., HBV coinfection), International guidelines do not provide indications to prefer any regimen over others concerning the tolerability profile. We aimed to assess advantages and disadvantages of the most prescribed STRs.Areas covered An extensive review of articles published in English language was conducted on PubMed, looking for evidence about STRs in naïve, HIV-infected population. Safety outcomes of registrational trials were assessed, giving priority to studies directly comparing STRs included in our research (abacavir/lamivudine/dolutegravir, tenofovir alafenamide/emtricitabine/bictegravir, lamivudine/dolutegravir, tenofovir alafenamide/emtricitabine/darunavir/cobicistat, tenovofir disoproxil fumarate/lamivudine/doravirine). Data from cohort studies and meta-analyses were also assessed, extrapolating the main evidence about the combinations of interest.Expert opinion Integrase inhibitors (InsTIs)-based regimens have few interruptions for adverse events and few drug-related adverse events, with tenofovir alafenamide/emtricitabine/dolutegravir and lamivudine/dolutegravir being the most tolerable ones. However, neuropsychiatric adverse events and metabolic issues could prompt the alternative use of darunavir or doravirine-based combinations, even if a superior safety profile of these combinations over InSTIs has yet to be demonstrated." @default.
- W3160218393 created "2021-05-24" @default.
- W3160218393 creator A5015921959 @default.
- W3160218393 creator A5016247442 @default.
- W3160218393 creator A5037360246 @default.
- W3160218393 creator A5041785868 @default.
- W3160218393 creator A5073132839 @default.
- W3160218393 date "2021-05-27" @default.
- W3160218393 modified "2023-10-17" @default.
- W3160218393 title "Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV" @default.
- W3160218393 cites W1549276187 @default.
- W3160218393 cites W1971947763 @default.
- W3160218393 cites W2007756030 @default.
- W3160218393 cites W2013376320 @default.
- W3160218393 cites W2017605567 @default.
- W3160218393 cites W2027284363 @default.
- W3160218393 cites W2027372478 @default.
- W3160218393 cites W2032586043 @default.
- W3160218393 cites W2039691644 @default.
- W3160218393 cites W2044141691 @default.
- W3160218393 cites W2051116409 @default.
- W3160218393 cites W2057851884 @default.
- W3160218393 cites W2068866500 @default.
- W3160218393 cites W2082407676 @default.
- W3160218393 cites W2087258915 @default.
- W3160218393 cites W2094241860 @default.
- W3160218393 cites W2139430929 @default.
- W3160218393 cites W2149185709 @default.
- W3160218393 cites W2151589354 @default.
- W3160218393 cites W2154725148 @default.
- W3160218393 cites W2172550071 @default.
- W3160218393 cites W2279171734 @default.
- W3160218393 cites W2317006258 @default.
- W3160218393 cites W2327535499 @default.
- W3160218393 cites W2327696366 @default.
- W3160218393 cites W2341136980 @default.
- W3160218393 cites W2510140996 @default.
- W3160218393 cites W2554692247 @default.
- W3160218393 cites W2556153964 @default.
- W3160218393 cites W2578798018 @default.
- W3160218393 cites W2600344958 @default.
- W3160218393 cites W2613086869 @default.
- W3160218393 cites W2690342936 @default.
- W3160218393 cites W2728117782 @default.
- W3160218393 cites W2742578179 @default.
- W3160218393 cites W2765874485 @default.
- W3160218393 cites W2766387045 @default.
- W3160218393 cites W2779343225 @default.
- W3160218393 cites W2791039963 @default.
- W3160218393 cites W2792742326 @default.
- W3160218393 cites W2794276766 @default.
- W3160218393 cites W2794800108 @default.
- W3160218393 cites W2802048935 @default.
- W3160218393 cites W2802578844 @default.
- W3160218393 cites W2803560531 @default.
- W3160218393 cites W2810502584 @default.
- W3160218393 cites W2889157553 @default.
- W3160218393 cites W2893518254 @default.
- W3160218393 cites W2897642221 @default.
- W3160218393 cites W2898175531 @default.
- W3160218393 cites W2899935160 @default.
- W3160218393 cites W2904481063 @default.
- W3160218393 cites W2912107318 @default.
- W3160218393 cites W2912906273 @default.
- W3160218393 cites W2914789356 @default.
- W3160218393 cites W2944376193 @default.
- W3160218393 cites W2945985905 @default.
- W3160218393 cites W2951303202 @default.
- W3160218393 cites W2953716972 @default.
- W3160218393 cites W2959761797 @default.
- W3160218393 cites W2962964639 @default.
- W3160218393 cites W2966066929 @default.
- W3160218393 cites W2970412797 @default.
- W3160218393 cites W2971524815 @default.
- W3160218393 cites W2976245304 @default.
- W3160218393 cites W2979917028 @default.
- W3160218393 cites W2986321983 @default.
- W3160218393 cites W2996250544 @default.
- W3160218393 cites W3004871263 @default.
- W3160218393 cites W3015062716 @default.
- W3160218393 cites W3015620945 @default.
- W3160218393 cites W3016600481 @default.
- W3160218393 cites W3031539151 @default.
- W3160218393 cites W3033333369 @default.
- W3160218393 cites W3044292104 @default.
- W3160218393 cites W3092046481 @default.
- W3160218393 cites W3104670616 @default.
- W3160218393 cites W3119498799 @default.
- W3160218393 cites W3145648936 @default.
- W3160218393 cites W4234693438 @default.
- W3160218393 cites W4244459571 @default.
- W3160218393 doi "https://doi.org/10.1080/14740338.2021.1931115" @default.
- W3160218393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34018892" @default.
- W3160218393 hasPublicationYear "2021" @default.
- W3160218393 type Work @default.
- W3160218393 sameAs 3160218393 @default.
- W3160218393 citedByCount "3" @default.
- W3160218393 countsByYear W31602183932022 @default.